Biochemical parameters (lactate dehydrogenase, serum albumin) as early predictor of severe dengue

Poornima Shankar, Prarthana B.


Background: Dengue fever (DF) is the arboviral infection with the largest incidence worldwide. Clinical expression of dengue virus infection varies from no symptoms to severe dengue with shock. It is the most rapidly spreading vector borne disease in the world. Nearly 100 million cases of Dengue fever and between 250,000 and 500,000 cases of severe dengue are annually reported to the WHO. The objective of this study was to study aims at determining the LDH and serum albumin levels as early parameter to predict the severity of Dengue illness.

Methods: A observational clinical study conducted at K.I.M.S hospital, Bangalore, Karnataka, a tertiary care hospital. Children admitted in KIMS Hospital, Bangalore, Karnataka, a tertiary care hospital, Serum LDH and serum albumin levels are measured using the blood sample taken on the 3rd day of fever after confirmation of dengue fever (NS1 Ag- positive).

Results: Study enrolled 150 patients with confirmed infection of Dengue virus who were admitted to paediatric unit between July 2014 and December 2016. Serum samples taken 72-96 hours within onset of fever were used for biochemical tests. Of 150 patients, 40 developed Severe Dengue (SD). Cases of SD had higher levels of lactate dehydrogenase (LDH) and low levels of serum albumin. Multivariate analysis showed that early alterations of LDH levels i.e.  Out of 40 patients who developed severe dengue, 37 patients i.e. 92.7% had raised levels of LDH with levels more than >600 IU and<3 levels of serum albumin 13 patients i.e 32.5% of severe dengue cases with P value of < 0.001, which showed significant association.

Conclusions: Early alterations of biochemical parameter like LDH and serum albumin can predict Severe Dengue in patients with acute dengue illness.


Keywords: Dengue fever (DF) , lactate dehydrogenase (LDH), Severe Dengue (SD).

Full Text:



Ministry of Tourism Indian Tourism Statistics. 2013. Available at Accessed on August 2016.

World Bank India Overview. 2013. Available at Accessed on August 2016.

Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet. 1998;352:971-7.

Bagchi S. Dengue bites India. CMAJ. 2009;180:E7.

Kakkar M. Dengue fever is massively under-reported in India, hampering our response. BMJ. 2012;345:e8574.

Yip WCL. Dengue haemorrhagic fever: current approaches to management. Medical Progress. 1980;7:13.

Centers for disease control and prevention (CDC): Ongoing dengue epidemic-Angola. Morb Mortal Wkly Rep. 2013;62:504-8.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al: Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions, Proc Natl Acad Sci USA. 2012;109:7439-44.

Durbin AP, Kirkpatrick BD, Pierce KK. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013;207:957-65.

Rosner B. Fundamentals of biostatistics, 5th Edition, Duxbury; 2000:80-240.

Riffenburg RH. Statistics in Medicine, second edition, Academic press; 2005:85-125.

Chye JK, Lim CT, Ng KB, Lim JMH, George R, Lam SK, et al. Vertical transmission of dengue. Clin Inf Dis. 1997;25:1374-7.

Liu CC, Huang KJ, Lin YS, Yeh TM, Liu HS, Lei HY, et al. Transient CD4/CD8 ratio inversion and aberrant immune activation during dengue virus infection. J Med Virol, 2002;68(2):241-52.

Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg, 1998;38:172-80.

Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health. 2007;12(9):1087-95.

Chakravarthi A, Kumaria R. Circulating levels of TNF-alpha in patients with dengue and dengue hemorrhagic fever during an outbreak. Indian J Med Res. 2006;123:25-30.

Ibrahim NM Cehong. Dengue hemorrhagic fever at Kuala Lumpur hospital; Retrospective study of 102 cases. Br J Clin Pract. 1995;49:189-91.

Nimmannitya S. Dengue and chikungunya virus infection in man in Thailand, 1962−64. Observations on hospitalized patients with haemorrhagic fever. Am J Trop Med Hyg. 1969;18(6):954-71.

Dengue: Clinical and public health aspects- transmission of dengue virus by Aedes aegypti. Centre Dis Cont. 1998:435-36.

Phase III trial to evaluate efficacy and safety of a dengue 1,2,3,4 (attenuated) vaccine 91. efficacy, safety and immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). Tetravalent Immunization against Dengue Efficacy Study. 2016.

Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). World Health Organization, Geneva, Switzerland; 2013.

Capeding MR. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebocontrolled trial. Lancet. 2014;384(9951):1358-65.

Sangkawahibha N, Rojanasuphot S, Ahandrik S. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. Am J Epidemiol. 1984;120:653-69.

Gubler DJ. Aedes aegypti and Aedes aegypti bone disease control in the 1990s. Top down or bottom up? Charles Franklin Craig Lecture. Am J Trop Med Hyg. 1989; 40:571-8.

Ayyub M, Khazindar AM, Lubbad EH, Barlas S, Alfi AY, Al-Ukayli S. Characteristics of dengue fever in a large public hospital, Jeddah, Saudi Arabia. 2006;18(2):9-13.

Biochemical Alterations as Markers of Dengue Hemorrhagic Fever. Luis Angel Villar-Centeno, Fredi Alexander Díaz-Quijano, and Ruth Aralí Martínez-Vega School of Medicine, and Centro de Investigaciones Epidemiológicas, Universidad Industrial de Santander, Bucaramanga, Colombia. Am J Trop Med Hyg. 2008;78(3):370-4.

Sunder Rao PSS, Richard J. An introduction to biostatistics, a manual for students in health sciences, New Delhi: Prentice hall of India. 4th edition; 2006:86-160.